CurrentBlue Cross Blue Shield - IowaPolicy N/A

Miscellaneous Investigational Treatments for Reflux Disease

Defines Wellmark/Blue Cross Blue Shield - Iowa coverage stance on select nonstandard treatments for gastroesophageal reflux disease (GERD), including primary Roux-en-Y gastric bypass in nonobese patients and upper esophageal sphincter assist devices; applies to plan determinations and providers submitting claims.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMiscellaneous Investigational Treatments for Reflux Disease

Policy CodePolicy N/A

Change TypePolicy renewed (annual review)

Effective DateN/A

Next Review DateN/A

Key ActionDocument failure or intolerance of optimized PPI therapy and conservative measures before considering investigational procedures or devices.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2investigational treatments listed

0RYGB studies in nonobese

2UES single-arm studies

through Feb 2026last literature update

Mar 2026most recent action

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Investigational and Not Medically Necessary Treatments

Investigational

The following treatments are considered investigational:

Investigational treatments: Primary Roux-en-Y Gastric Bypass (open or laparoscopic) surgery in individuals with a BMI < 30 kg/m2; Upper Esophageal Sphincter Assist Device (e.g., Reza Band®, Reflux Band®); All Category III (T) codes unless explicitly covered by another policy.BMI < 30 kg/m2 applies to RYGBP

Policy lists these as investigational due to insufficient evidence.

Roux-en-Y gastric bypass (RYGB) — evidence summary

Summary coverage stance based on available evidence:

RYGB for primary GERD in nonobese individuals: No studies were identified that have evaluated Roux-en-Y gastric bypass (RYGB) as a primary procedure for GERD in nonobese individuals (BMI < 30 kg/m2); clinical benefit for GERD-specific outcomes (disease status, quality of life, medication use, treatment-related morbidity) is unproven.

Evidence gap supports investigational/not medically necessary stance until comparative data with longer follow-up are available.

Upper esophageal sphincter (UES) assist devices — evidence summary

UES assist devices (e.g., Reza Band®, Reflux Band®) — evidence is limited to small single-arm studies with short follow-up.

UES assist device for reflux disease: Evidence consists of two single-arm observational studies that showed short-term improvement in Reflux Symptom Index (RSI) scores but lacked concurrent control groups and long-term follow-up; the longest reported follow-up was three months and device continuation rates were incomplete.RSI inclusion threshold noted in one study: RSI ≥ 13

Durability, comparative effectiveness, and impact on clinically meaningful outcomes remain uncertain; randomized controlled trials with longer follow-up are needed.

Antireflux surgery — patient selection

Coverage considerations referenced to professional guidance

Antireflux surgery candidacy: Before offering antireflux surgery, providers should document objective evidence of GERD and consider severity (for example LA grade C or D esophagitis or large hiatal hernia) or persistent, troublesome GERD symptoms; shared decision-making is recommended and lack of response to proton pump inhibitor (PPI) therapy predicts lack of response to surgery.

Recommendations align with AGA guidance; consider RYGB for GERD only in obese patients who are candidates and accept procedure risks and lifestyle changes.

The policy lists the following as investigational because available evidence is insufficient to demonstrate improved net health outcomes: a primary Roux-en-Y gastric bypass (RYGBP) — open or laparoscopic — when performed for GERD in individuals with a BMI < 30 kg/m2, and upper esophageal sphincter (UES) assist devices (for example, Reza Band®, Reflux Band®). Category III (temporary/T) codes are also considered investigational unless explicitly covered elsewhere.

A targeted review found no studies that evaluate Roux‑en‑Y gastric bypass as a primary procedure for treating GERD in nonobese individuals (those with a BMI ≤ 29.9 kg/m2). Because clinical benefit in this population has not been demonstrated, RYGB as a primary GERD procedure is not supported by the identified evidence.

Providers should counsel patients that objective evidence of GERD (for example, endoscopic findings or physiologic testing) and a documented trial of optimized proton pump inhibitor (PPI) therapy are important predictors of response to invasive anti‑reflux interventions. Per professional guidance, patients without objective GERD or those who have not responded to PPIs are less likely to benefit from surgical or device‑based anti‑reflux procedures.

For individuals with GERD who are nonobese (BMI < 30 kg/m2), the use of RYGBP as a primary anti‑reflux procedure is considered not proven / insufficient evidence to improve symptoms, quality of life, medication use, or treatment‑related morbidity because no comparative studies were identified.

Summary: Roux‑en‑Y gastric bypass for primary treatment of GERD in nonobese patients and upper esophageal sphincter assist devices are considered investigational or not medically necessary due to insufficient controlled evidence and limited follow‑up. Available UES device data are limited to small single‑arm studies with short (maximum 3‑month) follow‑up and uncertain durability.

Some therapies for reflux disease are emerging and lack sufficient published evidence to support coverage. For example, UES assist devices have data from a small number of single‑arm studies with short follow‑up; randomized controlled trials with larger populations and longer follow‑up are needed. Ongoing or unpublished clinical trials may affect future assessments and should be monitored.

Coding — Procedure, Category III, and Related Codes

Category III / Emerging Technology CodesmixedExperimental

Category III codes (T-codes)

All Category III codes will be considered investigational unless explicitly addressed as a covered service in a Wellmark BlueCross BlueShield Medical Coverage Policy.

Procedure CPT CodesCPT

43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption
1013T	Laparoscopy, surgical, implantation or replacement of lower esophageal sphincter neurostimulator electrode array and neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver, including cruroplasty and/or electronic analysis, when performed
1014T	Laparoscopic revision or removal, lower esophageal sphincter neurostimulator electrodes
1015T	Revision or removal, lower esophageal sphincter neurostimulator pulse generator or receiver
1016T	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), lower esophageal sphincter neurostimulator pulse generator/transmitter; intraoperative, with programming

Neurostimulator Analysis CPT CodesCPT

1017T	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), lower esophageal sphincter neurostimulator pulse generator/transmitter; subsequent, without reprogramming
1018T	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), lower esophageal sphincter neurostimulator pulse generator/transmitter; subsequent, with reprogramming

HCPCS / DMEHCPCS

E1399

Durable medical equipment, Miscellaneous

inv-15: BMI threshold for investigational RYGBP

BMI threshold<= 29.9 kg/m2

Policy applicationApplies to primary RYGBP proposed for GERD; individuals with BMI < 30 kg/m2 are in the investigational population

RationaleNo identified studies evaluate RYGB as primary GERD procedure in nonobese individuals; evidence insufficient to demonstrate net health benefit

inv-16: BMI threshold for RYGB population

Relevant population BMI≤ 29.9 kg/m2

Clinical context

Provider Actions — Authorization, Documentation, and Denial Risk

Denial Risk

Investigational treatments subject to denial

The following treatments for reflux disease are considered investigational and may be denied because the evidence is insufficient to determine an improvement in net health outcomes: primary Roux-en-Y Gastric Bypass (RYGBP) as a primary procedure for GERD in individuals with BMI < 30 kg/m2, and Upper Esophageal Sphincter (UES) Assist Devices (e.g., Reza Band™, Reflux Band®). ALL Category III (T) codes will be considered investigational unless explicitly addressed as a covered service in a Wellmark Blue Cross Blue Shield Medical Coverage Policy. For bariatric/metabolic surgery medical necessity criteria (BMI > 30) refer to Wellmark's Authorization Table.

Primary RYGBP for GERD in BMI < 30 kg/m2 — investigational/denial risk
Upper Esophageal Sphincter Assist Devices (Reza Band™, Reflux Band®) — investigational/denial risk
Category III (T) codes treated as investigational unless specifically covered

Denial Risk

UES device limited evidence

Evidence for UES assist devices is limited to small, single-arm observational studies with short follow-up (maximum reported 3 months). Results show some improvement in symptom scores (RSI) in a subset of patients but are limited by lack of randomized controlled trials, small sample sizes, and uncertain durability. Because of these limitations, claims may be denied or requests for additional clinical information may be required.

Background — Clinical Context and Rationale

Background: Gastroesophageal reflux disease (GERD) is a common disorder characterized by reflux‑related symptoms and complications. Initial management emphasizes lifestyle measures (weight loss when appropriate, head‑of‑bed elevation, smoking cessation) and medical therapy such as proton pump inhibitors (PPIs). Surgical options (for appropriately selected patients) include procedures such as laparoscopic fundoplication; RYGBP is an established bariatric operation for obesity‑related indications but has not been shown to be effective as a primary GERD procedure in nonobese patients.

Definitions — Devices, Procedures, and Populations

inv-32: Upper Esophageal Sphincter Assist Device (Reflux Band) definition

DefinitionAn external device worn around the neck during sleep that applies standardized pressure to the cricoid cartilage to augment upper esophageal sphincter function and reduce laryngopharyngeal reflux (e.g., Reflux Band, Reza Band).

MechanismProvides approximately 20–30 mmHg of external pressure (Reflux Band) to prevent gastric contents reaching the laryngopharynx.

Use caseStudied as an adjunct to PPI therapy for laryngopharyngeal or extraesophageal reflux; evaluated in small single‑arm studies with short follow-up.

inv-33: Roux-en-Y gastric bypass (RYGBP) definition

DefinitionRoux-en-Y gastric bypass (RYGBP) is a bariatric surgical procedure creating a small gastric pouch and attaching a Y-shaped section of small intestine to bypass the lower stomach, duodenum, and proximal jejunum, reducing caloric intake and absorption.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMiscellaneous Investigational Treatments for Reflux Disease

Policy CodePolicy N/A

Change TypePolicy renewed (annual review)

Effective DateN/A

Next Review DateN/A

Key ActionDocument failure or intolerance of optimized PPI therapy and conservative measures before considering investigational procedures or devices.

SourceLink

On This Page

Nonobese individuals with reflux disease uncontrolled by proton pump inhibitors (PPIs)

Policy implicationRYGB as primary GERD therapy in this population is considered investigational/not supported by evidence

inv-17: RSI threshold used in studies

RSI threshold (study inclusion)RSI ≥ 13

Study contextUsed in Slivers et al. 2016 single-arm study of UES assist device in extraesophageal reflux

Outcome measureReflux Symptom Index (RSI) used to track symptom change over 2–4 weeks

Longest follow-up reported = 3 months; only ~67% device use at 3 months in one study
High discontinuation rates for intolerance or poor symptom control
No randomized controlled trials identified

Prior Authorization

Evidence and prior response affect surgical approval

Referral for anti-reflux surgery should include shared decision-making and objective evidence of GERD. A lack of response to an adequate trial of PPI therapy predicts lack of response to anti-reflux surgery and should be considered in the decision process.

Confirm objective evidence of GERD prior to surgical referral
Document response (or nonresponse) to PPI therapy — lack of PPI response may predict poor surgical outcomes
Use shared decision-making to review risks, benefits, and alternatives

Documentation Required